News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Nov 28, 2012
Porton Down, UK, 28 November 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for
Nov 28, 2012
Porton Down, UK; November 28 2012: GW Pharmaceuticals plc (AIM:GWP) reports results from a Phase IIa exploratory study which has identified GW’s novel cannabinoid, GWP42004, as a potential new oral
Nov 12, 2012
Porton Down, UK; 12 November 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that its Managing Director, Justin Gover will be presenting at the Lazard Capital Markets 9th Annual Healthcare C
Oct 12, 2012
The results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month’s treatment with Sativex® (THC:CBD) oromucos
Oct 01, 2012
London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer.
Sep 13, 2012
London, UK; 13 September 2012: GW pharmaceuticals (LSE:GWP “GW”) is pleased to note the University of Reading’s press release, reproduced below, announcing the publication in the peer-reviewed journ
Jun 21, 2012
Porton Down, UK, 21 June 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, is pleased to note the announcement from i
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six m
May 22, 2012
Third phase III Sativex® cancer pain trial commences
May 08, 2012
Barcelona, Spain; Porton Down, UK; 8th May 2012: GW Pharmaceuticals plc (AIM:GWP) and Almirall S.A.

Pages